Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation

Wang, Jieting; Yu, Luying; Zhou, Ao; Liu, Jie; Wang, Kai; Luo, Ying; Wang, Fang

doi:10.3390/pharmaceutics13091520

Cited by 6 publications

(4 citation statements)

References 205 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adeno-associated viruses, lentiviruses, and adenoviruses are commonly used viral vectors due to their high transduction efficiency [43]. Non-viral vectors such as liposomes and nanoparticles offer advantages such as reduced immunogenicity and improved safety profiles [44]. There are several target transfer genes for AMI that have been investigated to date, but only a few are discussed subsequently.…”

Section: Gene Therapy For Acute Myocardial Infarctionmentioning

confidence: 99%

Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction

Khawaja

Siddiqui

Virani

et al. 2023

Genes

View full text Add to dashboard Cite

Acute myocardial infarction remains a significant cause of mortality worldwide and its burden continues to grow. Its pathophysiology is known to be complex and multifactorial, with several acquired and inherited risk factors. As advances in technology and medical therapy continue, there is now increasing recognition of the role that genetics play in the development and management of myocardial infarction. The genetic determinants of acute coronary syndrome are still vastly understudied, but the advent of whole-genome scanning and genome-wide association studies has significantly expanded the current understanding of genetics and simultaneously fostered hope that genetic profiling and gene-guided treatments could substantially impact clinical outcomes. The identification of genes associated with acute myocardial infarction can help in the development of personalized medicine, risk stratification, and improved therapeutic strategies. In this context, several genes have been studied, and their potential involvement in increasing the risk for acute myocardial infarction is being investigated. As such, this article provides a review of some of the genes potentially related to an increased risk for acute myocardial infarction as well as the latest updates in gene-guided risk stratification and treatment strategies.

show abstract

Section: Gene Therapy For Acute Myocardial Infarctionmentioning

confidence: 99%

Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction

Khawaja

Siddiqui

Virani

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…Compared with viral vectors, non-viral vectors can encapsulate more nucleic acids [12]. The preparation of non-viral vectors is simple and the production cost is much cheaper than that of viral vectors [13]. In addition, non-viral vectors possess lower immunogenicity than that of viral vectors [12].…”

Section: Non-viral Gene Therapeuticsmentioning

confidence: 99%

“…Lipid-based, polymeric nanoparticles, and protein/peptides are the main categories of non-viral gene delivery systems. To deliver gene cargos to the target cells with high efficiency, the employed vectors need to be well-designed, which should simultaneously possess favorable stability, desirable target affinity, optimal loading capacity, and satisfactory biocompatibility [13]. In order to achieve above goals in IPF treatment, herein we review the pathophysiological process of pulmonary fibrosis and summary gene-therapy strategies applied in treating IPF, especially the applications of non-viral vectors, hoping to accelerate the bench-to-bedside pace of non-viral gene therapy for IPF.…”

Section: Introductionmentioning

confidence: 99%

Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside

Huang

Gao

Cai³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by irreversible lung scarring, which achieves almost 80% five-year mortality rate. Undeniably, commercially available pharmaceuticals, such as pirfenidone and nintedanib, exhibit certain effects on improving the well-being of IPF patients, but the stubbornly high mortality still indicates a great urgency of developing superior therapeutics against this devastating disease. As an emerging strategy, gene therapy brings hope for the treatment of IPF by precisely regulating the expression of specific genes. However, traditional administration approaches based on viruses severely restrict the clinical application of gene therapy. Nowadays, non-viral vectors are raised as potential strategies for in vivo gene delivery, attributed to their low immunogenicity and excellent biocompatibility. Herein, we highlight a variety of non-viral vectors, such as liposomes, polymers, and proteins/peptides, which are employed in the treatment of IPF. By respectively clarifying the strengths and weaknesses of the above candidates, we would like to summarize the requisite features of vectors for PF gene therapy and provide novel perspectives on design-decisions of the subsequent vectors, hoping to accelerate the bench-to-bedside pace of non-viral gene therapy for IPF in clinical setting.

show abstract

“…Commercially available, non-viral liposomal delivery systems have therefore emerged at the forefront of therapeutics due to their high cellular membrane affinity, non-immunogenic response, and ease of production. However, these methods still suffer from low transfection efficiency and high cytotoxicity, compared to viral carriers [8]. Furthermore, the emergence of a subclass of non-viral delivery carriers utilizing coinage metals as a platform, in the form of nanoparticles, offers the advantages of low toxicity and high payload delivery.…”

Section: Introductionmentioning

confidence: 99%

Self-Assembled Monolayers Derived from Positively Charged Adsorbates on Plasmonic Substrates for MicroRNA Delivery: A Review

Hoang,

Tajalli,

Omidiyan

et al. 2023

JNT

View full text Add to dashboard Cite

MicroRNA (miRNA) has emerged as a promising alternative therapeutic treatment for cancer, but its delivery has been hindered by low cellular uptake and degradation during circulation. In this review, we discuss the various methods of delivering miRNA, including viral and non-viral delivery systems such as liposomes and nanoparticles. We also examine the use of nanoparticles for miRNA-based diagnostics. We focus specifically on non-viral delivery systems utilizing coinage metals in the form of nanoparticles and the use of self-assembled monolayers (SAMs) as a method of surface modification. We review the use of SAMs for the conjugation and delivery of small noncoding ribonucleic acid (ncRNA), particularly SAMs derived from positively charged adsorbates to generate charged surfaces that can interact electrostatically with negatively charged miRNA. We also discuss the effects of the cellular uptake of gold and other plasmonic nanoparticles, as well as the challenges associated with the degradation of oligonucleotides. Our review highlights the potential of SAM-based systems as versatile and robust tools for delivering miRNA and other RNAs in vitro and in vivo and the need for further research to address the challenges associated with miRNA delivery and diagnostics.

show abstract

Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation

Cited by 6 publications

References 205 publications

Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction

Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction

Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside

Self-Assembled Monolayers Derived from Positively Charged Adsorbates on Plasmonic Substrates for MicroRNA Delivery: A Review

Contact Info

Product

Resources

About